Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research
Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research
Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
CONCLUSIONS: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.PMID:38386807 | PMC:PMC10883683 | DOI:10.18632/oncotarget.28561 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Elisabetta De Matteis Maria Rosaria Tumolo Paolo Tarantino Mariangela Ciccarese Tiziana Grassi Francesco Bagordo Maria Rita De Giorgio Emanuele Rizzo Graziana Ronzino Source Type: research
Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research
Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research
Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
CONCLUSIONS: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.PMID:38386807 | PMC:PMC10883683 | DOI:10.18632/oncotarget.28561 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Elisabetta De Matteis Maria Rosaria Tumolo Paolo Tarantino Mariangela Ciccarese Tiziana Grassi Francesco Bagordo Maria Rita De Giorgio Emanuele Rizzo Graziana Ronzino Source Type: research
Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research
Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research
Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX
Oncotarget. 2024 Feb 5;15:90. doi: 10.18632/oncotarget.28462.NO ABSTRACTPMID:38329724 | PMC:PMC10852066 | DOI:10.18632/oncotarget.28462 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Huan Liu Guizhi Zhou Xin Fu Haiyan Cui Guangrui Pu Yao Xiao Wei Sun Xinhua Dong Libin Zhang Sijia Cao Guiqin Li Xiaowei Wu Xu Yang Source Type: research
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis
Oncotarget. 2024 Feb 5;15:91-103. doi: 10.18632/oncotarget.28512.ABSTRACTAbout 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients. Applying a machine lear...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: P A Shatalov N A Falaleeva E A Bykova D O Korostin V A Belova A A Zabolotneva A P Shinkarkina A Yu Gorbachev M B Potievskiy V S Surkova Zh V Khailova N A Kulemin Denis Baranovskii A A Kostin A D Kaprin P V Shegai Source Type: research
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Oncotarget. 2024 Feb 5;15:104-105. doi: 10.18632/oncotarget.28536.NO ABSTRACTPMID:38329729 | PMC:PMC10852055 | DOI:10.18632/oncotarget.28536 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Yunfei Liao Lulu Chen Yong Feng Jacson Shen Yan Gao Gregory Cote Edwin Choy David Harmon Henry Mankin Francis Hornicek Zhenfeng Duan Source Type: research
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland
In conclusion, NTRK gene fusion is infrequent in patients with PTC. Linkage of biobank samples to EHRs is feasible in describing the characteristics and outcomes of patients with PTC and potentially other cancer types.PMID:38329731 | PMC:PMC10852057 | DOI:10.18632/oncotarget.28555 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Wei Zhang Arndt A Schmitz Roosa E Kallionp ää Merja Per älä Niina Pitk änen Mikko Tukiainen Erika Alanne Korinna J öhrens Renate Schulze-Rath Bahman Farahmand Jihong Zong Source Type: research
